Meld | $7,000,000 | (Jan 15, 2026)
Musical AI | $4,500,000 | (Jan 15, 2026)
Harmattan AI | $200,000,000 | (Jan 15, 2026)
Certified by Founder
Lodge
T-Therapeutics Ltd
start up
United Kingdom
- Cambridge
- 16/11/2023
- Series A
- $59,707,000
T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.
We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
- Industry Biotechnology Research
- Website https://t-therapeutics.com/
- LinkedIn https://www.linkedin.com/company/t-therapeutics/about/
Aikido Security | $60,000,000 | (Jan 15, 2026)
Flip (US) | $20,000,000 | (Jan 15, 2026)
Atomic Insights | $10,000,000 | (Jan 15, 2026)
osapiens | $100,000,000 | (Jan 15, 2026)
Axol Bioscience Ltd. | $28,000,000 | (Jan 15, 2026)